TY - JOUR
T1 - Efficacy and safety of topical tazarotene
T2 - A review
AU - Talpur, Rakhashandra
AU - Cox, Katherine
AU - Duvic, Madeleine
PY - 2009/2
Y1 - 2009/2
N2 - Background: Tazarotene (Tazorac®, Avage®, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor-βγ topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris. Objectives: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders. Methods: We reviewed the published literature available on PubMed for safety and efficacy of topical tazarotene gel or cream preparations. Results/conclusions: Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer. Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies. Daily application of tazarotene is effective with sustained benefits and limited local side effects.
AB - Background: Tazarotene (Tazorac®, Avage®, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor-βγ topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris. Objectives: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders. Methods: We reviewed the published literature available on PubMed for safety and efficacy of topical tazarotene gel or cream preparations. Results/conclusions: Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer. Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies. Daily application of tazarotene is effective with sustained benefits and limited local side effects.
KW - Acne
KW - Actinic damage
KW - Efficacy
KW - Psoriasis
KW - Retinoid
KW - Tazarotene
UR - http://www.scopus.com/inward/record.url?scp=67649086703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649086703&partnerID=8YFLogxK
U2 - 10.1517/17425250902721250
DO - 10.1517/17425250902721250
M3 - Review article
C2 - 20213916
AN - SCOPUS:67649086703
SN - 1742-5255
VL - 5
SP - 195
EP - 210
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
IS - 2
ER -